Skip to search formSkip to main contentSkip to account menu

pexelizumab

Known as: h5G1.1-SC, h5G1.1-scFv 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (2)

Antibodies, Monoclonal, HumanizedSingle-Chain Antibodies
antigen binding

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2012
Review
2012
Complement Activation: An Emerging Player in the Pathogenesis of Cardiovascular Disease
A wealth of evidence indicates a fundamental role for inflammation in the pathogenesis of cardiovascular disease (CVD… 
2012
2012
Serious infection after acute myocardial infarction: incidence, clinical features, and outcomes.
Highly Cited
2011
Highly Cited
2011
Diagnosing acute myocardial infarction in patients with left bundle branch block.
Highly Cited
2010
Highly Cited
2010
A Model for Predicting Mortality in Acute ST-Segment Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention: Results From the Assessment of Pexelizumab in Acute…
Background—Accurate models to predict mortality are needed for risk stratification in patients with ST-segment elevation… 
Highly Cited
2010
Highly Cited
2010
Prior coronary artery bypass graft patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention.
2010
2010
Role of the complement components C5 and C3a in a mouse model of myocardial ischemia and reperfusion injury
Objective: Ischemic heart disease is the leading cause of death worldwide. The complement system plays a major role in… 
Highly Cited
2008
Highly Cited
2008
ST-Segment Recovery and Outcome After Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction: Insights From the Assessment of Pexelizumab in Acute Myocardial Infarction…
Background— Primary percutaneous coronary angioplasty is an effective and widely adopted treatment for acute myocardial… 
Highly Cited
2007
Highly Cited
2007
Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: a randomized controlled trial.
CONTEXT Reperfusion with percutaneous transluminal coronary intervention (PCI) is effective at improving outcomes in patients… 
Review
2007
Review
2007
Innate immunity-mediated allograft rejection and strategies to prevent it.
Highly Cited
2004
Highly Cited
2004
Terminal complement blockade with pexelizumab during coronary artery bypass graft surgery requiring cardiopulmonary bypass: a randomized trial.
CONTEXT Inflammation and ischemia-reperfusion injury during coronary artery bypass graft (CABG) surgery requiring cardiopulmonary… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)